Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
BURLINGAME, Calif., March 09, 2017 -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will host and provide a live webcast for its R&D Day, starting at 9:00 AM ET on March 14, 2017 in New York City.
The event will highlight the emerging role of the adenosine axis in immuno-oncology and its potential to address the limitations of existing agents. Additionally, Corvus will provide updates on its progress in clinical trials evaluating its lead CPI-444 program as well as the company’s pipeline.
Speakers at the event include:
- Jonathan D. Powell, MD, PhD (Johns Hopkins University)
- Lawrence Fong, MD (University of California, San Francisco)
- Richard Miller, MD (Corvus Co-Founder, President and CEO)
| R&D Day Webcast and Conference Call Details | |||||
| Event Title: | R&D Day Update: The Emergence of the Adenosine Pathway in Cancer Immunotherapy | ||||
| Date: | Tuesday, March 14, 2017 | ||||
| Time: | 9:00 - 12:00 p.m. ET | ||||
| Webcast: | The live webcast and slide presentation can be accessed at https://event.webcasts.com/starthere.jsp?ei=1137880 | ||||
An archive of the webcast will be available in the Investors section of the company's website for 30 days following the event.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
Tecentriq® is a registered trademark of Genentech.
Corvus Contact: Jason Coloma SVP, Chief Business Officer Corvus Pharmaceuticals, Inc. +1-650-900-4511 [email protected] Media Contact: Julie Normart Pure Communications +1-415-946-1087 [email protected]
